Pharma major Cipla's Ugandan subsidiary, Cipla Quality Chemical Industries (CiplaQCIL), today said it is looking to partner with the government of Uganda to increase access to cancer treatments.
The company through its facility in Kampala, Uganda, manufactures antiretroviral, antimalarial and hepatitis medicines to treat HIV/AIDS, malaria and hepatitis.
"Faced with the growing burden of cancer in Uganda and Africa, we once again intent on partnering with the government of Uganda to increase access to cancer treatments," a company statement said.
The company has already partnered with the Uganda government for HIV/AIDS and malaria treatments.
Cipla, the parent company, has been a major player in cancer treatment in the country and other parts of the world.
"The disparities in cancer survival rates between Uganda and the developed countries can be bridged through developing local solutions to this local problem through public private partnerships," the statement added.
The company estimates around eight lakh people are suffering from cancer in Uganda, but only 4 per cent of those are able to access proper care.
It pegs the cancer survival rates at just 13 per cent, except for breast cancer which stands at 46 per cent.
CiplaQCIL in November 2016 had said that it is evaluating an initial public offering (IPO) to list on Uganda bourse. Renaissance Capital (Kenya) was appointed as the official book runner.
However, there is no clarity on the timeline of the IPO so far.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)